Compare Gilead Sciences, Inc. (GILD) vs PayPal Holdings, Inc. (PYPL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs PayPal Holdings, Inc. — how do they compare? Gilead Sciences, Inc. trades at $134.56 (market cap $163.51B), while PayPal Holdings, Inc. trades at $57.45 (market cap $48.97B). The key difference: Gilead Sciences, Inc. is far larger — about 3.3× PayPal Holdings, Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | PYPL | |
|---|---|---|
Market Cap | $163.51B | $48.97B |
Sector | Health | Financials |
52-Week High | $155.80 | $78.22 |
52-Week Low | $108.22 | $39.08 |
Enterprise Value | $178.05B | $49.04B |
Dividend Yield | 2.49% | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PayPal (PYPL) surged 20.24% to $56.96 following a $53 billion takeover bid from Stripe and Advent International at $60.50 per share. The stock trades near resistance at $57 with RSI indicating overbought conditions. Fundamentally, PYPL shows strong profitability with a 15% net income margin and attractive valuation at a P/E of 10.42. Recent earnings beat expectations in Q1 2026 with EPS of $1.34 versus $1.27 forecast.
The acquisition offer creates near-term upside potential, though regulatory approval risks remain. Long-term investors face competition in digital payments and execution challenges. Analyst consensus is mixed with a $49.50 price target below current levels, suggesting caution despite bullish technical momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About PayPal Holdings, Inc.
PayPal Holdings, Inc. operates as a technology platform company that enables digital and mobile payments on behalf of consumers and merchants. The Company offers online payment solutions. PayPal Holdings serves customers worldwide.
Read more on PYPL →
